» Articles » PMID: 31196948

Impact of the Revised Haemodynamic Definition on the Diagnosis of Pulmonary Hypertension in Patients with Systemic Sclerosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2019 Jun 15
PMID 31196948
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). We explored the impact of the updated haemodynamic definition of pulmonary hypertension (PH), as proposed by the 6th World Symposium on Pulmonary Hypertension.

Methods: In this single-centre retrospective analysis, patients with SSc who had right heart catheterisation (RHC) were included. We compared the prior PH definition to the updated PH definition. The prior definition classified PH as mean pulmonary arterial pressure (mPAP) ≥25 mmHg and further divided into pre-capillary PH (PAH and PH due to lung disease and/or hypoxia), post-capillary PH, and combined pre- and post-capillary PH groups. For the updated definition, PH was classified as mPAP >20 mmHg and further divided into the different groups. We validated our findings in the DETECT cohort.

Results: Between 2005 and March 2019, 268 RHCs were performed in this single-centre cohort. Using the prior definition, 137 (51%) were diagnosed with PH, with 89 classified as pre-capillary PH (56 with PAH and 33 with PH due to lung disease and/or hypoxia), 29 as post-capillary PH, and 19 as combined pre- and post-capillary PH. When the updated definition was applied to the cohort, seven out of 131 (5%) with no PH were reclassified to pre-capillary PH (PAH (n=1), PH due to lung disease (n=3) and post-capillary PH (n=3)). In those with mPAP 21-24 mmHg, with no left heart or significant lung disease, one out of 28 (4%) in our cohort and four out of 36 (11%) in the DETECT cohort were reclassified as PAH.

Conclusion: The updated PH definition does not appear to have a significant impact on the diagnosis of PH in two different screening cohorts.

Citing Articles

A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS (HAPPINESS study): protocol and baseline data for an observational study.

Takeyama S, Hanaoka H, Hashimoto A, Ishii Y, Shimizu Y, Takeuchi T BMC Rheumatol. 2025; 9(1):25.

PMID: 40012072 PMC: 11863849. DOI: 10.1186/s41927-025-00474-2.


Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.

Xanthouli P, Uesbeck P, Lorenz H, Blank N, Eichstaedt C, Harutyunova S Arthritis Res Ther. 2024; 26(1):136.

PMID: 39026360 PMC: 11256414. DOI: 10.1186/s13075-024-03363-0.


Impact of the 2022 pulmonary hypertension definition on haemodynamic classification and mortality in patients with aortic stenosis undergoing valve replacement.

Maeder M, Weber L, Pohle S, Chronis J, Baty F, Rigger J Eur Heart J Open. 2024; 4(3):oeae037.

PMID: 38812478 PMC: 11135639. DOI: 10.1093/ehjopen/oeae037.


The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.

Li Y, Qian J, Dong X, Zhao J, Wang Q, Wang Y Arthritis Res Ther. 2024; 26(1):109.

PMID: 38802957 PMC: 11129383. DOI: 10.1186/s13075-024-03338-1.


Connective tissue disease-associated pulmonary hypertension: A comprehensive review.

Khangoora V, Bernstein E, King C, Shlobin O Pulm Circ. 2023; 13(4):e12276.

PMID: 38088955 PMC: 10711418. DOI: 10.1002/pul2.12276.


References
1.
Pan J, Lei L, Zhao C . Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018; 36(6):1095-1102. View

2.
Galie N, McLaughlin V, Rubin L, Simonneau G . An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2018; 53(1). PMC: 6351332. DOI: 10.1183/13993003.02148-2018. View

3.
Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

4.
Khanna D, McLaughlin V . Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. Am J Respir Crit Care Med. 2015; 192(9):1032-3. DOI: 10.1164/rccm.201509-1881ED. View

5.
Kovacs G, Berghold A, Scheidl S, Olschewski H . Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34(4):888-94. DOI: 10.1183/09031936.00145608. View